ライフサイエンスコーパス: EBOV

1 EBOV causes hemorrhagic fever, organ damage, and shock c

2 EBOV GP vaccine with Matrix-M adjuvant is well tolerated

3 EBOV is a negative-sense RNA virus that can infect human

4 EBOV RNA was detected in semen samples from 30% of the s

5 EBOV-specific CD8+ and CD4+ T-cell responses were signif

6 EBOV-targeting antibodies cross-react with other Ebolavi

7 EBOV/Mak was inactivated (> 6 log(10)) by 70% ethanol af

8 0 samples (31.4%) versus in 21 of 70 (30.0%) EBOV-positive samples by repeat qRT-PCR (overall concord

9 of enrolled HCWs were reactive to at least 1 EBOV protein: 159 (28.1%) were seroreactive for anti-gly

10 ity improvement compared to the 53 ng mL(-1) EBOV antigen detection limit of the existing rapid EBOV

11 OV) was successfully used during the 2013-16 EBOV epidemic.

12 ic Republic of the Congo, the site of a 2014 EBOV outbreak.

13 In the wake of the 2013-2016 EBOV epidemic, and despite advancement of promising cand

14 PBMCs were collected from 23/26 EBOV IgG-negative participants.

15 onducted in 230 healthy adults to evaluate 4 EBOV GP antigen doses as single- or 2-dose regimens with

16 A total of 966 EBOV antibody-positive survivors and 2350 antibody-negat

17 Immunogenicity following acute EBOV infection may exist along a spectrum and absence of

18 st the potential to use Ct values from acute EBOV diagnostic specimens for index patients as an early

19 ctional response following survival of acute EBOV disease has not been well characterized.

20 e tissues after challenge with mouse-adapted EBOV (MA-EBOV).

21 e polyclonal IgG fragments, F(ab')2, against EBOV.

22 hile retaining the parental activity against EBOV and Bundibugyo virus.

23 vator (CIITA) has antiviral activity against EBOV.

24 ially efficient therapeutic approach against EBOV disease in humans.

25 its precursor in protective efficacy against EBOV and SUDV in guinea pigs.

26 5, protects nonhuman primates (NHPs) against EBOV and SUDV infection when delivered four days post in

27 ne, and toremifene) were more potent against EBOV.

28 Several mAbs protected against EBOV disease in animals, including one mAb that targeted

29 he putative correlates of protection against EBOV.

30 diated cytotoxicity (ADCC) responses against EBOV and SUDV.

31 rrently is no licensed human vaccine against EBOV.

32 All EBOV GP vaccine formulations were well tolerated.

33 de that correlates are not universal for all EBOV vaccines.

34 Although EBOV infection results in significant damage to the live

35 ous two-dose Ad26,MVA regimens containing an EBOV insert induce strong, durable humoral and cellular

36 search resulted in the recent approval of an EBOV-targeted vaccine by European and US regulatory agen

37 and safer than a parallel construct with an EBOV GP lacking the MLD (VSV-EBOVDeltaMLD).

38 weeks, seroconverted against both RABV-G and EBOV-GP.

39 equivalent degrees of inhibition of LASV and EBOV glycoprotein (GP)-bearing pseudoviruses; three (clo

40 ug cocktail that could inhibit both LASV and EBOV.IMPORTANCE Lassa and Ebola viruses continue to caus

41 partners: PS, EBOV virus-like particle, and EBOV glycoprotein/vesicular stomatitis virus pseudovirio

42 tivation, a property shared by MARV VP40 and EBOV VP24.

43 We assessed associations between anti-EBOV IgG seroreactivity, defined as >=2.5 units/mL and r

44 r EBOV RNA in blood by qRT-PCR, and for anti-EBOV-specific IgM and IgG antibodies by enzyme-linked im

45 Human anti-EBOV Glycoprotein (GP) IgG titers were measured using a

46 ith adjuvant showed a rapid increase in anti-EBOV GP IgG titers with peak titers observed on Day 35 r

47 ith adjuvant showed a rapid increase in anti-EBOV GP immunoglobulin G titers with peak titers observe

48 study towards the goal of induction of anti-EBOV immunity in multiple at-risk populations.

49 We investigated the potential anti-EBOV effect of amodiaquine in a well-characterized nonhu

50 articipant who had PBMCs which produced anti-EBOV-specific antibodies upon stimulation.

51 3 participants had PBMCs which produced anti-EBOV-specific IgG antibodies upon stimulation with EBOV-

52 vaccination, and then treated with the anti-EBOV GP mAb MIL77 starting 3 days postexposure show no e

53 dentification of small molecules that arrest EBOV-host membrane fusion.

54 Our study provides a benchmark for assessing EBOV vaccine-induced immunity.

55 VLPs) and for egress and spread of authentic EBOV.

56 inant vesicular stomatitis virus (VSV)-based EBOV vaccine was clinically tested (NCT02283099).

57 Besides EBOV, two additional ebolaviruses, Sudan (SUDV) and Bund

58 ned to extend the breadth of immunity beyond EBOV.

59 ed the potency of eight drugs known to block EBOV entry with their potency as inhibitors of LASV entr

60 ase with the small-molecule PF-429242 blocks EBOV entry and infection.

61 us noncoding RNAs (ncRNAs) derived from both EBOV and MARV during infection of both bat and human cel

62 detected several candidate miRNAs from both EBOV and the closely related Marburg virus (MARV).

63 ted animals from death and disease caused by EBOV, SUDV, and BDBV.

64 eracted with PACT, a host protein engaged by EBOV VP35 to inhibit RIG-I signaling.

65 ring shipping and handling, mNGS followed by EBOV-specific capture probe enrichment in a U.S. genomic

66 h the patient's blood sample was negative by EBOV qRT-PCR testing, identification of viral reads by m

67 Within infected cells, EBOV downregulates STAT1 mRNA and interferon signaling,

68 to treat acute infections (e.g. Coronavirus, EBOV, ZIKV, IAV and measles), and also topically for the

69 le inhibitors of filovirus entry destabilize EBOV GP and uncovered evidence that the most potent inhi

70 Serology assays can detect EBOV-specific antigens and antibodies cost-effectively w

71 nostic tests based on immunoassays to detect EBOV antigens.

72 nsor's extraordinary capability of detecting EBOV antigen at ultralow concentration compared to exist

73 antenna-based biosensor successfully detects EBOV soluble glycoprotein (sGP) in human plasma down to

74 to expand protective breadth against diverse EBOV strains and evaluated the impact of vaccine dosing

75 to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35,

76 to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared with placebo on Day 35,

77 characterize peripheral immune cells during EBOV infection in rhesus monkeys.

78 Filoviridae, including Ebola (EBOV) and Marburg (MARV) viruses, are emerging pathogens

79 f three different ebolavirus species, Ebola (EBOV), Sudan, and Reston viruses.

80 and cellular immune responses to Ebolavirus (EBOV) glycoprotein.

81 Zaire ebolavirus (EBOV) causes Ebola virus disease (EVD), which carries a

82 tective efficacy against three Ebolaviruses: EBOV, SUDV, and BDBV.

83 ent of MLAV in a different genus than either EBOV or MARV.

84 ombinant vesicular stomatitis virus encoding EBOV antigens.

85 s replication sites correlated with enhanced EBOV disease progression in specific conditions; at a hi

86 ch is particularly important when evaluating EBOV vaccine responses and immuno-therapeutics.

87 Current experimental EBOV monoclonal antibodies (mAbs) are ineffective agains

88 ings from the serologic testing of blood for EBOV-specific antibodies, molecular testing for EBOV in

89 t CD68+ macrophages are the target cells for EBOV in affected ganglia.

90 on of cathepsin B, known to be essential for EBOV entry.

91 All 126 participants tested negative for EBOV RNA in blood by qRT-PCR.

92 blood of 26 participants tested negative for EBOV-specific IgG antibodies by ELISA.

93 rst rigorous assessment of the potential for EBOV to encode viral miRNAs and provides evidence contra

94 y proteins act as cell surface receptors for EBOV, and that the interaction between TIM and phosphati

95 relapsed EVD, is unlikely to pose a risk for EBOV transmission.

96 Overall, 22.5% of HCWs were seroreactive for EBOV.

97 ages, the latter a recommended surrogate for EBOV.

98 We tested for EBOV RNA in blood by qRT-PCR, and for anti-EBOV-specific

99 V-specific antibodies, molecular testing for EBOV in blood and semen, and serologic testing of periph

100 t a strategy for a host-targeted therapy for EBOV.

101 in these tissues, which were collected from EBOV-infected cynomolgus macaques.

102 criptional changes in tissues collected from EBOV-Makona-infected cynomolgus macaques.

103 plexity of antibody-mediated protection from EBOV disease highlights the structural constraints of Fc

104 mplex with cleaved Ebola virus glycoprotein (EBOV GP(CL)) reveals that binding of the mAb structurall

105 vel synthetic anti-Ebola virus glycoprotein (EBOV-GP) DNA vaccines as a strategy to expand protective

106 ors with sequelae had a significantly higher EBOV-specific CD8+ and CD4+ T-cell response.

107 ent in a U.S. genomics laboratory identified EBOV reads in 22 of 70 samples (31.4%) versus in 21 of 7

108 LAV belonging to a distinct genus.IMPORTANCE EBOV and MARV, members of the family Filoviridae, are hi

109 orts the concept that NK cells accumulate in EBOV-infected tissues and can contribute to viral pathog

110 protective efficacy than ADI-15878 alone in EBOV-challenged guinea pigs.

111 No differences in EBOV-specific immunoglobulin G, antinuclear antibody, or

112 ival benefit or decrease of disease signs in EBOV-infected animals.

113 More violent events increased EBOV transmission (P = .03).

114 studies in mice found these epitopes induce EBOV-neutralizing antibodies and protect against lethal

115 showing potent inhibition against infectious EBOV Zaire (0.09 muM) and MARV (0.64 muM).

116 Each dilution tested reduced the infectious EBOV/Mak titer by ~5 log(10) within one min.

117 Our study provides novel insight into EBOV-host interactions and elucidates how host responses

118 We investigated EBOV-specific CD8+ and CD4+ T-cell responses in 37 Sierr

119 Infection induced lasting EBOV-specific immunoglobulin G (IgG) antibodies, but the

120 A chimeric VSV expressing the full-length EBOV GP (VSV-EBOV) containing the MLD was substantially

121 d CD4+ T-cell responses in 37 Sierra Leonean EBOV disease survivors with (n = 19) or without (n = 18)

122 Lethal EBOV infection has been documented to decrease the level

123 lizing antibodies and protect against lethal EBOV challenge.

124 00% protection to BALB/c mice against lethal EBOV challenge.

125 ) could fully protect ferrets against lethal EBOV, SUDV, and BDBV infection, and a single 25-mg/kg do

126 administration on protection against lethal EBOV-Makona challenge in cynomolgus macaques.

127 oration, were 100% protective against lethal EBOV-Makona challenge.

128 the apparent loss of immune cells in lethal EBOV infection.

129 In lethal EBOV infections, levels of both NK and T cells decline d

130 and Rousettus cells, MLAV VP35 behaved like EBOV and MARV VP35s, inhibiting virus-induced activation

131 vivors, when compared to results from a live EBOV neutralisation assay.

132 ivity, specificity and correlation with live EBOV neutralisation were greater for the VSV-based pseud

133 after challenge with mouse-adapted EBOV (MA-EBOV).

134 ty of licensed medical countermeasures makes EBOV a critical human pathogen.

135 a marked increase in antibody titers to most EBOV proteins and affinity maturation to GP is associate

136 to determine seroprevalence against multiple EBOV antigens among HCWs of Boende Health Zone, Democrat

137 the trivalent vaccine bound and neutralized EBOV and SUDV at equivalent levels and BDBV at only a sl

138 In total, 9 new EBOV genomes (3 complete genomes, and an additional 6 >=

139 ue culture infectious dose(50) (TCID(50)) of EBOV/Mak was exposed to DAL at ambient temperature.

140 disease outbreaks, as well as the ability of EBOV to persist in the environment under certain conditi

141 an important and poorly documented aspect of EBOV infection and progression.

142 thus promising candidates for the control of EBOV.

143 s challenged with a uniformly lethal dose of EBOV one day following vaccination, and then treated wit

144 Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EB

145 Receipt of 2 doses of EBOV GP with adjuvant showed a rapid increase in anti-EB

146 Following endocytosis of EBOV, the GP1 domain is cleaved by cellular cathepsins i

147 esearch regarding the nature and function of EBOV ncRNAs.

148 es targeted to EBOV GP; however, handling of EBOV is limited to containment level 4 laboratories.

149 losterically protect against inactivation of EBOV by premature triggering of GP2.

150 The rapid and substantial inactivation of EBOV/Mak by DAL suggests that use of this hygiene produc

151 lts demonstrate >= 6 log(10) inactivation of EBOV/Mak dried on prototypic surfaces by EDS or formulat

152 genesis studies confirmed that inhibition of EBOV viral entry is mediated by the direct interaction w

153 ied ridaifen-B as a potent dual inhibitor of EBOV and MARV.

154 FcgammaR humanized mouse challenge models of EBOV disease.

155 this review, we describe the pathogenesis of EBOV and summarize the current status of EBOV vaccine de

156 r understanding the biology and pathology of EBOV infections.

157 cal techniques, we assessed the potential of EBOV ncRNAs to function as viral miRNAs.

158 iral reads by mNGS confirmed the presence of EBOV coinfection.

159 We also studied the presence of EBOV-specific immunoglobulin G, antinuclear antibodies,

160 of this candidate vaccine for prevention of EBOV disease is warranted.

161 nd karyopherin alpha proteins, properties of EBOV VP24.

162 Both endosomal proteolysis of EBOV GP and binding of mAb FVM09 displace this loop, the

163 es that are supporting active replication of EBOV.

164 and lymphatic organs are important sites of EBOV infection and that dysregulating the function of th

165 issues, indicating they are primary sites of EBOV infection.

166 of EBOV and summarize the current status of EBOV vaccine development and treatment of EVD.

167 We evaluated the suitability of EBOV GP pseudotyped human immunodeficiency virus type 1

168 nd phosphatidylserine (PS) on the surface of EBOV mediates the EBOV-host cell attachment.

169 es harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal ant

170 Focusing our validation efforts on EBOV, we found evidence contrary to the idea that these

171 an-induced events, had the largest impact on EBOV transmission.

172 This study sheds light on EBOV tropism, replication dynamics, and elicited immune

173 m a screen of FDA-approved drugs as a potent EBOV viral entry inhibitor, via binding to EBOV glycopro

174 in all vaccinees, we detected highly potent EBOV-neutralizing antibodies with activities comparable

175 biological role of computationally predicted EBOV ncRNAs.

176 h-risk groups of contacts to help prioritize EBOV disease investigation and control efforts.

177 IM-4 and the following binding partners: PS, EBOV virus-like particle, and EBOV glycoprotein/vesicula

178 ntigen detection limit of the existing rapid EBOV immunoassay.

179 e safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated w

180 e safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated w

181 Using single-round replicating EBOV minigenomes, we investigated the effect of the 3' t

182 Serum EBOV-neutralizing and binding antibodies using wild-type

183 Serum EBOV-neutralizing and binding antibodies using wild-type

184 for inactivating Ebola virus-Makona strain (EBOV/Mak) on stainless-steel carriers per ASTM E2197-11.

185 ver, not observed in individuals who survive EBOV infection.

186 hibitor development and refinement targeting EBOV.IMPORTANCE The most recent Ebola virus disease outb

187 Our results demonstrate that EBOV can infect peripheral ganglia and results in gangli

188 Further, we demonstrated that EBOV can induce satellite cell and neuronal apoptosis an

189 Although it is well established that EBOV results in severe organ damage, our understanding o

190 In parallel, we observed that EBOV-GP DNA vaccination induced long-term immune respons

191 We show that EBOV infection of a GNPTAB knockout cell line is impaire

192 The EBOV sensor exhibits substantial fluorescence intensity

193 uman monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and humans when ad

194 Of all the EBOV proteins, only VP35 is able to overcome the defect

195 mimics the conserved interaction between the EBOV GP core and its glycan cap beta17-beta18 loop to in

196 ated in chickens and was able to express the EBOV glycoprotein (GP) gene at high level.

197 evaluated as a vaccine vector to express the EBOV GP gene.

198 icular stomatitis virus (VSV) expressing the EBOV glycoprotein (GP) might selectively target brain tu

199 ine (PS) on the surface of EBOV mediates the EBOV-host cell attachment.

200 The mucin-like domain (MLD) of the EBOV GP may enhance virus immune system evasion.

201 Multiple-injection regimens of the EBOV-GP DNA vaccine, delivered by intramuscular administ

202 RNA synthesis in an individual patient, the EBOV genome exists around a dominant viral genome sequen

203 monoclonal antibodies (mAbs) that target the EBOV glycoprotein (GP) have demonstrated potent protecti

204 o monoclonal antibody products targeting the EBOV membrane glycoprotein.

205 tide on viral replication and found that the EBOV polymerase initiates replication opposite the 3'-CC

206 Therefore, the EBOV GP pseudotyped VSV neutralisation assay reported he

207 imeric vesicular stomatitis viruses with the EBOV glycoprotein substituted for the VSV glycoprotein s

208 t mice when the MLD was expressed within the EBOV glycoprotein than when EBOV lacked the mucin-like d

209 , and VP24 proteins were compared with their EBOV and MARV homologs for innate immune pathway modulat

210 anged from 40 to 100 pN, suggesting that TIM-EBOV interactions are mechanically comparable to previou

211 dings, the biophysical properties of the TIM-EBOV interaction, such as the mechanical strength of the

212 t EBOV viral entry inhibitor, via binding to EBOV glycoprotein (GP).

213 In contrast to EBOV, only a few vaccines have been developed against MA

214 l glands, and lymphoid tissues contribute to EBOV pathogenesis.

215 Our results suggest high exposure to EBOV among HCWs and provide additional evidence for asym

216 Epidemiologic data were linked to EBOV real-time reverse-transcription polymerase chain re

217 tivity to the protective function of mAbs to EBOV GP, we selected anti-GP mAbs targeting representati

218 antibody binding, and affinity maturation to EBOV proteins.

219 with mutations in GNPTAB, are refractory to EBOV, whereas cells from their healthy parents support i

220 ures of viral and host factors as related to EBOV pathogenesis.

221 a longitudinal study of B cell responses to EBOV in four survivors of the 2014 West African outbreak

222 eria and evaluated their immune responses to EBOV.

223 o assess neutralising antibodies targeted to EBOV GP; however, handling of EBOV is limited to contain

224 closer relationship of MLAV to MARV than to EBOV but also are consistent with MLAV belonging to a di

225 ncRNAs from both viruses, we identified two EBOV ncRNAs in our sequencing data that were near-matche

226 activating Ebola virus (Makona C07 variant) (EBOV/Mak) within an organic load in suspension was evalu

227 entifying drugs that block both Ebola virus (EBOV) and Lassa virus (LASV), two unrelated but highly p

228 SHERLOCK) diagnostics targeting Ebola virus (EBOV) and Lassa virus (LASV), with both fluorescent and

229 viridae Because the filoviruses Ebola virus (EBOV) and Marburg virus (MARV) modulate host innate immu

230 quencing (mNGS) to detect Zaire Ebola virus (EBOV) and other potential pathogens from whole-blood sam

231 Recent outbreaks of Ebola virus (EBOV) and severe acute respiratory syndrome coronavirus

232 glycoproteins (GPs) from Zaire Ebola virus (EBOV) and Sudan Ebola virus (SUDV) and is designed to ex

233 for ultrasensitive detection of Ebola virus (EBOV) antigens.

234 MARV) is a filovirus related to Ebola virus (EBOV) associated with human hemorrhagic disease.

235 Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae.

236 Ebola virus (EBOV) causes epidemics with high mortality yet remains u

237 en previously evaluated against Ebola virus (EBOV) challenge.

238 Ebola virus (EBOV) continues to pose a significant threat to human he

239 Ebola virus (EBOV) continues to pose significant threats to global pu

240 In response to the Ebola virus (EBOV) crisis of 2013-2016, a recombinant vesicular stoma

241 esus macaques that succumbed to Ebola virus (EBOV) disease from 5 to 8 days post exposure.

242 Ebola virus (EBOV) disease has killed thousands of West and Central A

243 Ebola virus (EBOV) disease outbreaks, as well as the ability of EBOV

244 al illness epidemics such as of Ebola virus (EBOV) disease.

245 re more likely to be exposed to Ebola virus (EBOV) during an outbreak compared to people in the gener

246 rtemisinin, the beneficial anti-Ebola virus (EBOV) effect observed could possibly be attributed to th

247 Ebola virus (EBOV) entry into cells is mediated by its spike glycopro

248 The Ebola virus (EBOV) envelope glycoprotein (GP) is a membrane fusion ma

249 e the most recent outbreak, the Ebola virus (EBOV) epidemic remains one of the world's public health

250 Ebola virus (EBOV) epidemics pose a major public health risk.

251 is virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully us

252 Since its discovery in 1976, Ebola virus (EBOV) has caused numerous outbreaks of fatal hemorrhagic

253 icacy against the highly lethal Ebola virus (EBOV) in humans is almost impossible due to obvious ethi

254 Ebola virus (EBOV) inclusion bodies (IBs) are cytoplasmic sites of nu

255 can mediate protection against Ebola virus (EBOV) infection through direct neutralization as well as

256 screen for genes essential for Ebola virus (EBOV) infection.

257 Given that the Ebola virus (EBOV) infects a wide array of organs and cells yet displ

258 Ebola virus (EBOV) is a highly lethal member of the Filoviridae famil

259 Ebola virus (EBOV) is an enveloped, single-stranded RNA virus that ca

260 s for household transmission of Ebola virus (EBOV) is important to guide preventive measures during E

261 Evidence from the 2013-2016 Ebola virus (EBOV) outbreak indicated that different genotypes of the

262 viral pathogenicity.IMPORTANCE Ebola virus (EBOV) outbreaks can claim numerous lives and also devast

263 a major role in propagation of Ebola virus (EBOV) outbreaks.

264 antibody repertoire against the Ebola virus (EBOV) proteome was characterized in an acutely infected

265 Ebola virus disease.IMPORTANCE Ebola virus (EBOV) remains a high-priority pathogen since it continue

266 A key step in the Ebola virus (EBOV) replication cycle involves conformational changes

267 Persistence of Ebola virus (EBOV) RNA in semen samples from survivors was determined

268 versus nontargeted violence on Ebola virus (EBOV) transmission in Democratic Republic of the Congo (

269 The Ebola virus (EBOV) VP40 matrix protein (eVP40) orchestrates assembly

270 member of the Ebolavirus genus, Ebola virus (EBOV), and ineffective against outbreak-causing Bundibug

271 fusion proteins including HIV, Ebola virus (EBOV), influenza A virus (IAV) and Epstein Barr virus (E

272 ead by close contact, including Ebola virus (EBOV), severe acute respiratory syndrome coronavirus (SA

273 Ebola virus (EBOV), species Zaire ebolavirus, may persist in the seme

274 Several Ebola virus (EBOV)-specific and, more recently, pan-ebolavirus antibo

275 approved therapy against lethal Ebola virus (EBOV).

276 ory syncytial virus (HRSV), and Ebola virus (EBOV).

277 le miRNA candidates produced by Ebola virus (EBOV).

278 uently lethal disease caused by Ebola virus (EBOV).

279 ous study in which we used an attenuated VSV-EBOV with no MLD that expressed green fluorescent protei

280 In contrast, VSV-EBOV containing the MLD showed substantially better targ

281 In contrast, VSV-EBOV eliminated the tumors and showed relatively little

282 onses to internal VSV proteins following VSV-EBOV immunization.

283 VSV expressing the full-length EBOV GP (VSV-EBOV) containing the MLD was substantially more effectiv

284 Neither VSV-EBOV nor VSV-EBOVDeltaMLD showed substantive infection o

285 A single-dose regimen of VSV-EBOV revealed a safe and immunogenic profile and demonst

286 d substantially more progeny faster than VSV-EBOV.

287 targeting human brain tumors with these VSV-EBOVs.

288 tients (64.5%) tested in Kinshasa, DRC, were EBOV positive by quantitative reverse transcriptase PCR

289 essed within the EBOV glycoprotein than when EBOV lacked the mucin-like domain.

290 Here, we compared chimeric VSVs in which EBOV GP replaces the VSV glycoprotein, thereby reducing

291 While EBOV-specific immune responses to this candidate vaccine

292 hich at least 9 (42.9%) were coinfected with EBOV.

293 rs (HCWs) have elevated risk of contact with EBOV-infected patients, particularly if safety precautio

294 protected against subsequent infection with EBOV and that neutralising antibodies to the viral surfa

295 virus was detected in cells inoculated with EBOV/Mak exposed to NaOCl (0.5% or 1%), PCMX (0.12% to 0

296 We enrolled all confirmed persons with EBOV disease who were the first case patient in a househ

297 pecific IgG antibodies upon stimulation with EBOV-specific GP and NP antigens.

298 howed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5

299 and binding antibodies using wild-type Zaire EBOV (ZEBOV) or pseudovirion assays were 3- to 9-fold hi

300 Ebolaviruses Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) cause human d